Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.
Looking for leads, investment insights, or competitive intelligence?
News about Gilead Sciences
The PrEP drug will be publicly funded in New Zealand for those at high risk for HIV infection.
Juno's stock is up a staggering 76% since rumors of the Celgene deal emerged last week.
The FDA approved 46 novel drugs in 2017 versus 22 in 2016.
The FDA approved Spark Therapeutics' Luxturna on Tuesday.